Artificial Intelligence-Based Virtual Reality on Patient With Upper Gastrointestinal Endoscopy (Virtual)

September 25, 2026 updated by: Eman Abdelfatah Shokr, Al-Zaytoonah University of Jordan

Effect of Artificial Intelligence-Based Virtual Reality on Patient-Reported Outcomes During Upper Gastrointestinal Endoscopy: A Randomized Controlled Trial

This randomized controlled trial evaluates whether an artificial intelligence-based virtual reality (AI-VR) relaxation intervention can improve patient outcomes during upper gastrointestinal endoscopy. Patients undergoing elective upper gastrointestinal endoscopy will be randomly assigned in a 1:1 ratio to either an AI-VR intervention group or a routine-care control group. Participants in the intervention group will receive a 10-15-minute AI-VR relaxation session immediately before the endoscopy, while participants in the control group will receive routine care. The study will assess patients' anxiety, pain perception, physiological parameters, and satisfaction in relation to the endoscopy procedure. The findings will help determine whether AI-VR can improve patient comfort and the overall endoscopy experience.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Upper gastrointestinal endoscopy is an important diagnostic and therapeutic procedure; however, patients may experience anxiety, pain, discomfort, and physiological changes before and during the procedure. These experiences may negatively affect patient comfort and satisfaction. This study was designed to evaluate the effect of an artificial intelligence-based virtual reality (AI-VR) relaxation intervention on patient-reported and physiological outcomes among patients undergoing elective upper gastrointestinal endoscopy.

This study uses a randomized controlled trial design. Eligible patients undergoing elective upper gastrointestinal endoscopy will be randomly assigned in a 1:1 ratio to either an intervention group or a routine-care control group. The intervention group will receive a 10-15-minute AI-VR relaxation session immediately before undergoing upper gastrointestinal endoscopy. The control group will receive routine care according to the usual clinical practice.

The AI-VR intervention is intended to provide a relaxation experience before the endoscopic procedure. Patient outcomes will be assessed using validated measures of anxiety and pain, together with physiological parameters and patient satisfaction. Anxiety will be assessed using the State-Trait Anxiety Inventory (STAI), pain perception will be assessed using the Visual Analog Scale (VAS), and patient satisfaction will be assessed using the Patient Satisfaction Questionnaire (PSQ). Physiological parameters will also be assessed at the prespecified assessment time points.

The primary purpose of the study is to determine whether the AI-VR intervention improves patient outcomes during upper gastrointestinal endoscopy compared with routine care. Outcomes of interest include anxiety level, pain perception, physiological responses, and patient satisfaction.

Randomization will be performed using a computer-generated random sequence. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. Eligible participants will be enrolled after confirmation of eligibility and informed consent and will then be assigned to their respective study groups according to the concealed allocation sequence.

Data will be analyzed using IBM SPSS Statistics version 26.0. Appropriate statistical tests will be used to compare outcomes between the intervention and control groups and to examine relationships among anxiety, pain, satisfaction, and other study variables.

The study is intended to provide evidence regarding the potential role of AI-based virtual reality as a non-pharmacological intervention for reducing anxiety and discomfort and improving physiological responses and satisfaction among patients undergoing upper gastrointestinal endoscopy.

Study Type

Interventional

Enrollment (Actual)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amman, Jordan, 00000
        • Al zaytoonah University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

Participants will be eligible for inclusion if they:

  1. Are within the prespecified age range for the study ([insert minimum and maximum age
  2. Are scheduled to undergo elective upper gastrointestinal endoscopy.
  3. Are able to understand the study procedures and communicate effectively.
  4. Are willing to participate in the study and provide informed consent.

Exclusion Criteria

Participants will be excluded if they:

  1. Have a condition that prevents them from safely participating in the virtual reality intervention.
  2. Have significant visual, auditory, cognitive, or neurological impairment that would interfere with the use of the virtual reality intervention or completion of the study assessments.
  3. Have previously participated in this study.
  4. Are unable or unwilling to provide informed consent.
  5. Require an urgent or emergency upper gastrointestinal endoscopy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AI-Based Virtual Reality Group

Artificial Intelligence-Based Virtual Reality Relaxation

Artificial Intelligence-Based Virtual Reality Relaxation

No Intervention: Routine Care Control Group

non

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Anxiety During Upper Gastrointestinal Endoscopy
Time Frame: Anxiety (STAI) Baseline (pre-intervention) and immediately after the endoscopy procedure Pain intensity (VAS) Immediately after the endoscopy procedure Patient satisfaction (PSQ) Immediately after the endoscopy procedure Physiological parameters

Patient anxiety will be assessed using the State-Trait Anxiety Inventory (STAI). Anxiety scores will be compared between the artificial intelligence-based virtual reality intervention group and the routine-care control group to evaluate the effect of the intervention on patient anxiety during upper gastrointestinal endoscopy. The STAI consists of 20 items for assessing state anxiety, with total scores ranging from 20 to 80; higher scores indicate greater anxiety.

Anxiety (STAI) Baseline (pre-intervention) and immediately after the endoscopy procedure Pain intensity (VAS) Immediately after the endoscopy procedure Patient satisfaction (PSQ) Immediately after the endoscopy procedure Physiological parameters

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2026

Primary Completion (Actual)

January 5, 2026

Study Completion (Actual)

March 7, 2026

Study Registration Dates

First Submitted

September 21, 2026

First Submitted That Met QC Criteria

September 25, 2026

First Posted (Actual)

September 29, 2026

Study Record Updates

Last Update Posted (Actual)

September 29, 2026

Last Update Submitted That Met QC Criteria

September 25, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 1000/4/3/196/26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the study did not establish a data-sharing arrangement for individual-level participant data. The data contain potentially identifiable participant information and will be retained securely by the research team in accordance with applicable ethical and institutional requirements. De-identified aggregate results will be reported in publications arising from the study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.